Tech Company Financing Transactions
Entero Therapeutics Funding Round
Entero Therapeutics, based in Boca Raton, secured $3 million from private investors.
Transaction Overview
Company Name
Announced On
8/11/2025
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Seed
Investors
Proceeds Purpose
The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
777 Yamato Road 502
Boca Raton, FL 33431
USA
Boca Raton, FL 33431
USA
Phone
Website
Email Address
Overview
Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Paolone
Browse more venture capital transactions:
Prev: 8/11/2025: SetPoint Medical venture capital transaction
Next: 8/11/2025: BinSentry venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs